0001209191-18-012484.txt : 20180222
0001209191-18-012484.hdr.sgml : 20180222
20180222164622
ACCESSION NUMBER: 0001209191-18-012484
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180220
FILED AS OF DATE: 20180222
DATE AS OF CHANGE: 20180222
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GRYSKA DAVID W
CENTRAL INDEX KEY: 0001202335
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-12400
FILM NUMBER: 18633194
MAIL ADDRESS:
STREET 1: 749 N MARY AVE
CITY: SUNNYVALE
STATE: CA
ZIP: 94085
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: INCYTE CORP
CENTRAL INDEX KEY: 0000879169
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
IRS NUMBER: 943136539
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1801 AUGUSTINE CUT-OFF
CITY: WILMINGTON
STATE: DE
ZIP: 19803
BUSINESS PHONE: 3024986700
MAIL ADDRESS:
STREET 1: 1801 AUGUSTINE CUT-OFF
CITY: WILMINGTON
STATE: DE
ZIP: 19803
FORMER COMPANY:
FORMER CONFORMED NAME: INCYTE CORP
DATE OF NAME CHANGE: 20030318
FORMER COMPANY:
FORMER CONFORMED NAME: INCYTE GENOMICS INC
DATE OF NAME CHANGE: 20000710
FORMER COMPANY:
FORMER CONFORMED NAME: INCYTE PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19930902
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-02-20
0
0000879169
INCYTE CORP
INCY
0001202335
GRYSKA DAVID W
1801 AUGUSTINE CUT-OFF
WILMINGTON
DE
19803
0
1
0
0
Executive Vice President, CFO
Common Stock
2018-02-20
4
F
0
1070
86.03
D
12922
D
Common Stock
2018-02-21
4
S
0
1952
85.56
D
10970
D
Represents shares withheld to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.
Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated.
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person.
Represents weighted average sale price. Actual sale prices ranged from $85.11 - $86.28.
Includes an aggregate of 10,294 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
/s/ David W. Gryska
2018-02-22